SCHEMBL4490424

SCHEMBL4490424

Cc1c(C(C2=C(O)C(Cc3ccccc3)OC2=O)c2cccs2)[nH]c2ccc(F)cc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.34
HTR2A P28223 1/20 0.33
MEN1 O00255 5/20 0.33
KMT2A Q03164 5/20 0.33
MAPT P10636 5/20 0.32
TP53 P04637 1/20 0.32
ALDH1A1 P00352 4/20 0.32
KDM4E B2RXH2 3/20 0.32
MLKL Q8NB16 1/20 0.31
LMNA P02545 2/20 0.31
ATM Q13315 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
CNR1 P21554 2/20 0.31
USP2 O75604 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
GAA P10253 2/20 0.30
HPGD P15428 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
GLA P06280 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1376569 0.89 MLKL (0.39) CSF1RHTR2AMEN1KMT2AMAPT
SCHEMBL4502363 0.86 CNR1 (0.35) CSF1RHTR2AMEN1KMT2AMAPT
SCHEMBL1379124 0.71 CYP19A1 (0.34) MEN1KMT2AKDM4ELMNACNR1
SCHEMBL1376629 0.71 TOP1 (0.36) HTR2AMEN1KMT2AKDM4ELMNA
SCHEMBL4502803 0.69 PARP1 (0.33) MEN1KMT2AKDM4E
SCHEMBL4488588 0.67 MLKL (0.40) CSF1RHTR2AMEN1KMT2AMAPT
SCHEMBL4488597 0.67 MLKL (0.40) CSF1RHTR2AMEN1KMT2AMAPT
SCHEMBL8236712 0.67 MLKL (0.34) MEN1KMT2AMAPTALDH1A1MLKL
SCHEMBL1379227 0.67 MLKL (0.41) CSF1RHTR2AMEN1KMT2AMAPT
SCHEMBL4493732 0.66 OPRM1 (0.40) CSF1RHTR2AMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612099-B2 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-03 US disclosed
US-7612099-B2 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-03 US disclosed
US-7612099-B2 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-03 US disclosed
EP-1957483-A1 NOVEL VINYLOGOUS ACIDS DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-08-20 EP disclosed
WO-2007063010-A1 NOVEL VINYLOGOUS ACIDS DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-07 WO disclosed
US-20070129421-A1 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. 2007-06-07 US disclosed
US-20070129421-A1 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. 2007-06-07 US disclosed
US-20070129421-A1 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129421-A1 Vinylogous acid derivatives CMA1, TPSG1, TPSAB1 CSF1R 2855/4885HTR2A 2869/4885MEN1 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.